Enliven Therapeutics Balance Sheet
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics financial position
At the end of fiscal 2025, Enliven Therapeutics reported total assets of $476.2 million, up 46.2% from a year earlier against total liabilities of $16.6 million. Shareholders' equity stood at $459.6 million, or 96.5% of assets. The company held $98.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 28.66, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 98.90M | 124.12M | 100.14M | 75.54M | 48.31M | 47.70M | 4.94M |
| Short-Term Investments | 363.73M | 189.32M | 153.01M | 0 | 41.97M | 40.52M | 23.97M |
| Total Current Assets | 474.88M | 318.13M | 266.15M | 77.75M | 92.70M | 90.41M | 30.62M |
| Property, Plant & Equipment | 34.00K | 458.00K | 742.00K | 890.00K | 250.00K | 349.00K | 442.00K |
| Long-Term Investments | — | — | — | 0 | — | — | — |
| Total Assets | 476.17M | 325.76M | 271.87M | 83.30M | 93.65M | 90.84M | 33.30M |
| Accounts Payable | 2.16M | 1.34M | 532.00K | 3.44M | 2.36M | 1.97M | 1.66M |
| Total Current Liabilities | 16.57M | 15.91M | 25.89M | 9.71M | 7.21M | 6.25M | 4.20M |
| Total Liabilities | 16.57M | 15.91M | 25.96M | 10.37M | 7.62M | 6.41M | 4.38M |
| Shareholders' Equity | 459.60M | 309.85M | 245.91M | -76.83M | -42.89M | 84.44M | -48.85M |
| Retained Earnings | -347.17M | -243.47M | -154.45M | -82.86M | -147.50M | -96.11M | -54.75M |
| Net Cash (Debt) | 462.62M | 313.44M | 253.15M | 75.54M | 90.28M | 88.22M | 28.91M |
| Shares Outstanding | 59.44M | 48.94M | 41.29M | 3.57M | 26.29M | 17.55M | 702.51K |
This table shows 7 annual periods of Enliven Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a balance sheet?